Septerna (NASDAQ:SEPN) Price Target Raised to $48.00

Septerna (NASDAQ:SEPN) had its price target upped by JPMorgan Chase & Co. from $38.00 to $48.00 in a research note released on Wednesday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Other equities research analysts have also issued reports about the company. JonesTrading upped their price target on Septerna from $43.00 to $62.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Stifel Nicolaus set a $49.00 price objective on Septerna in a research note on Tuesday, August 11th. Truist Financial boosted their target price on Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Guggenheim increased their target price on shares of Septerna from $45.00 to $51.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $49.00 price target on shares of Septerna in a report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.44.

Septerna Stock Down 1.9%

Shares of NASDAQ SEPN opened at $40.00 on Wednesday. The stock has a market capitalization of $1.87 billion, a PE ratio of -74.07 and a beta of 2.29. The firm has a fifty day moving average of $36.85 and a 200-day moving average of $30.28. Septerna has a 52-week low of $11.70 and a 52-week high of $51.10.

Septerna (NASDAQ:SEPN) last issued its earnings results on Monday, August 10th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.14. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%.The business had revenue of $26.75 million for the quarter, compared to analyst estimates of $19.22 million. Equities research analysts expect that Septerna will post -1.36 EPS for the current fiscal year.

Insider Buying and Selling at Septerna

In other Septerna news, insider Samira Shaikhly sold 11,798 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $30.06, for a total transaction of $354,647.88. Following the transaction, the insider owned 793 shares in the company, valued at $23,837.58. The trade was a 93.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Daniel D. Long sold 15,000 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $35.51, for a total value of $532,650.00. Following the completion of the sale, the senior vice president directly owned 96,412 shares of the company’s stock, valued at $3,423,590.12. The trade was a 13.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 72,828 shares of company stock valued at $2,684,314 over the last three months. 5.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Septerna

Institutional investors and hedge funds have recently bought and sold shares of the stock. TRV GP V LLC acquired a new stake in Septerna in the second quarter valued at approximately $208,160,143,000. TRV GP VI LLC acquired a new position in shares of Septerna during the second quarter worth $141,048,460,000. BlackRock Inc. purchased a new position in shares of Septerna in the second quarter valued at $64,706,000. Jupiter Topco LLC purchased a new position in shares of Septerna in the second quarter valued at $43,723,000. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Septerna by 86.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock valued at $75,698,000 after purchasing an additional 1,260,409 shares during the period.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.